Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK, Ranbaxy And Others Expected To Face Questioning From India Regulator On U.S. FDA Drug List

This article was originally published in PharmAsia News

Executive Summary

India's drug regulator is expected to ask makers in the country to supply data on adverse reactions to drugs. The new concern was sparked by the U.S. FDA listing 20 drugs with such problems, at least six of them sold in India. The six are heparin, ivermectin, nitroglycerine, octreotide acetate, quetiapine and warfarin. The drugs controller general of India is expected to seek data from Cipla, Lupin, Ranbaxy Laboratories, Sun Pharmaceuticals and Torrent Pharmaceuticals, all of India, as well as U.K.-based GlaxoSmithkline Pharmaceuticals, makers or one or more of the drugs. D.G. Shah, the Indian Pharmaceutical Alliance's secretary general, said that would be normal practice for the DCGI. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts